Join Now
On July 28, 2025, Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical and wellness company, announced its Q1FY26 standalone and consolidated financial results. Despite near-term challenges, the company remains optimistic about achieving its ambitious FY2030 goals of $2 billion in revenue with a 25% EBITDA margin.
Financial Overview: Revenue and Profitability
Piramal Pharma reported consolidated revenue from operations at ₹1,934 crores for Q1FY26, a marginal 1% decline from ₹1,951 crores in Q1FY25. Excluding the impact of destocking in a key CDMO product, revenue growth was in the early double digits, showcasing resilience in its core operations.
Key Financial Metrics
| Particulars | Q1FY26 | Q1FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations | 1,934 | 1,951 | (1)% |
| CDMO | 997 | 1,057 | (6)% |
| CHG | 637 | 631 | 1% |
| PCH | 302 | 263 | 15% |
| EBITDA | 165 | 224 | (26)% |
| EBITDA Margin | 9% | 11% | – |
| PAT (after exceptional item) | (82) | (89) | 8% |
EBITDA margins contracted to 9% from 11% due to inventory destocking, though improved profitability in overseas CDMO facilities provided some offset. The net-debt-to-EBITDA ratio stood at 2.6x, reflecting stable financial management.
Business Segment Highlights
Contract Development and Manufacturing Organization (CDMO)
The CDMO segment recorded a 6% revenue decline to ₹997 crores, primarily due to destocking in a large on-patent product. However, the base business achieved mid-teens growth, driven by overseas facilities. The Aurora facility in Canada successfully passed a USFDA inspection with zero observations, reinforcing Piramal’s best-in-class quality record since 2011.
Key Achievements:
- Groundbreaking for capacity expansion at Lexington, US, to boost sterile injectable drug production.
- Growth in nutrition supplements and generic API business.
- Cost optimization through enhanced procurement and operational excellence.
Complex Hospital Generics (CHG)
The CHG segment saw a modest 1% growth to ₹637 crores, impacted by the timing of institutional orders for inhalation anesthesia products. Growth is expected to accelerate in subsequent quarters, supported by USFDA approval for the Digwal facility in India.
Piramal Consumer Healthcare (PCH)
The PCH segment delivered robust 15% growth, reaching ₹302 crores, driven by power brands and e-commerce. Power brands, contributing 49% to PCH sales, grew 18% year-on-year, fueled by products like Little’s and i-range.
PCH Growth Drivers:
- E-commerce sales surged 41% YoY, accounting for 23% of PCH revenue.
- Launched seven new products in Q1FY26.
- Investments in media and promotions reached 13% of PCH sales.
Strategic Outlook and Sustainability
Nandini Piramal, Chairperson, highlighted the company’s trajectory toward its FY2030 aspirations. Despite biotech funding challenges impacting early-stage CDMO projects, the company’s diversified portfolio and operational improvements position it for long-term success. Piramal’s sustainability efforts were recognized with an ESG rating of 61 for FY2024 by NSE Sustainability Ratings.
Earnings Conference Call
Piramal Pharma will host a conference call on July 29, 2025, from 9:30 AM to 10:15 AM IST to discuss these results. Investors can join via this link for seamless access.
Read the PDF of the Official Press Release of Piramal Pharma Limited
About Piramal Pharma Limited
Piramal Pharma operates across 171 global facilities, offering integrated solutions through its CDMO, CHG, and PCH businesses. With a presence in over 100 countries, the company continues to innovate in pharmaceuticals and consumer wellness. For more details, visit Piramal Pharma’s official website.